myo-029
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2004 (NCT00563810)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Growth/differentiation factor 8INHIBITOR
MSTN inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108051 ↗
Also known as
- human recombinant immunoglobulin g1 anti-gdf8 monoclonal antibody
- myo-029
- myo-029
- myo-029
- myo-029
- stamulumab
- stamulumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00104078 | Phase 1/Phase 2 (Phase 2) | Feb 1, 2005 | Pfizer, Wyeth |
| NCT00563810 | Phase 1 | Oct 1, 2004 | Pfizer, Wyeth |
Showing 2 of 2 trials
Page 1 / 1